logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 9994587 B1

PDFFull Text
Date of Patent:
Jun. 12, 2018

Filed:

Mar. 02, 2015

Hiv protease inhibitors

Applicant:

Merck Canada Inc., Kirkland, Québec, CA;

Inventors:

John A. McCauley, Maple Glen, PA (US);

David Jonathan Bennett, Winchester, MA (US);

Christopher J. Bungard, Lansdale, PA (US);

Thomas J. Greshock, Collegeville, PA (US);

M. Katharine Holloway, Lansdale, PA (US);

Peter D. Williams, Harleysville, PA (US);

Christian Beaulieu, Laval, CA;

Sheldon Crane, Ile Perrot, CA;

Stephanie Lessard, St-Jean-sur-Richeliu, CA;

Daniel Mckay, Milton, MA (US);

Carmela Molinaro, Colonia, NJ (US);

Oscar Miguel Moradei, Burlington, MA (US);

Vijayasaradhi Sivalenka, Singapore, SG;

Vouy Linh Truong, Pierrefonds, CA;

Satyanarayana Tummanapalli, Singapore, SG;

Assignees:

Merck Sharp & Dohme Corp., Rahway, NJ (US);

Merck Canada Inc., Kirkland, Province of Quebec, CA;

Attorneys:

Carol S. Quagliato

John C. Todaro

Primary Examiner:

Shawquia Jackson

Int. Cl.
CPC ...
C07D 498/10 (2006.01); C07D 265/30 (2006.01); A61K 31/5375 (2006.01); C07D 413/12 (2006.01); A61K 31/5377 (2006.01); C07D 417/14 (2006.01); C07D 413/14 (2006.01); C07D 487/04 (2006.01); C07D 471/04 (2006.01); C07D 413/06 (2006.01); C07D 265/36 (2006.01); A61K 31/5386 (2006.01); A61K 45/06 (2006.01);
U.S. Cl.
CPC ...
C07D 498/10 (2013.01); A61K 31/5375 (2013.01); A61K 31/5377 (2013.01); A61K 31/5386 (2013.01); A61K 45/06 (2013.01); C07D 265/30 (2013.01); C07D 265/36 (2013.01); C07D 413/06 (2013.01); C07D 413/12 (2013.01); C07D 413/14 (2013.01); C07D 417/14 (2013.01); C07D 471/04 (2013.01); C07D 487/04 (2013.01);
Abstract

The present invention is directed to 2,6-morpholine derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein Z, Z, V, V, V, R, R, and X are defined herein. The invention also relates to methods of using the 2,6-morpholine derivatives of the invention for the inhibition of HV protease, the inhibition of HV replication, the prophylaxis of infection by HIV, the treatment of infection by HIV, and the prophylaxis, treatment, and delay in the onset or progression of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.

Find Patent Forward Citations

Loading…